Clinical trial
CT-2103 vs Gemcitabine or Vinorelbine for the Treatment of PS = 2 Patients With Chemotherapy Naive Advanced Non-Small Cell Lung Cancer (NSCLC): A Phase III Study
NCT00054197 is registered in ClinicalTrials.gov with CTI BioPharma as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- CT-2103 vs Gemcitabine or Vinorelbine for the Treatment of PS = 2 Patients With Chemotherapy Naive Advanced Non-Small Cell Lung Cancer (NSCLC): A Phase III Study
- Lead sponsor
- CTI BioPharma
- Phase
- Phase 3
- Overall status
- Terminated
- Start date
- January 31, 2003
- Completion date
- October 31, 2004
- Enrollment
- Not reported
- Sites
- 10
Conditions
As the registry lists them; a condition with its own page is linked.
lung cancer